BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Indications For ONIVYDE In The U.S
BZ 注意：作为与益普生签订的出售肿瘤资产协议（包括ONIVYDE）的一部分，梅里马克制药有资格获得额外付款，但可能获得高达4.5亿美元的付款，前提是ONIVYDE在美国的潜在新适应症获得批准